MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland. Show more

Location: Dorfstrasse 29, Zug, 6300, Switzerland | Website: https://www.moonlaketx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

3.39B

52 Wk Range

$31.42 - $58.26

Previous Close

$53.38

Open

$53.48

Volume

371,758

Day Range

$53.41 - $54.99

Enterprise Value

3.045B

Cash

425.1M

Avg Qtr Burn

-41.6M

Insider Ownership

15.33%

Institutional Own.

96.69%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Sonelokimab Details
Hidradenitis suppurativa

Phase 3

Data readout

Sonelokimab Details
Psoriatic arthritis

Phase 3

Data readout

Sonelokimab Details
Hidradenitis suppurativa

Big Mover™

Susp. Mover™

Phase 3

Data readout

Sonelokimab Details
Axial spondyloarthritis

Phase 2

Data readout

Sonelokimab Details
Palmoplantar pustulosis

Phase 2

Data readout

Sonelokimab Details
Psoriatic arthritis and Axial spondyloarthritis

Phase 2

Initiation